 HAIFA, Israel, July 08, 2021 GLOBE NEWSWIRE -- Pluristem Therapeutics Inc. Nasdaq:PSTI TASE:PSTI the Company, a leading biotechnology company announced today that it is bringing its Acute Respiratory Distress Syndrome ARDS associated with COVID-19 Phase II studies to clinical readout. The Companys COVID-19 program included over 100 patients across two Phase II studies in the U.S., Europe and Israel, and in compassionate use and expanded access programs in the U.S. and Israel. The analysis will be based on 89 patients enrolled in the previously announced two Phase II studies, which investigated the safety and efficacy of Pluristems PLX cells as a treatment for severe COVID-19 cases complicated by ARDS. 